Tag Archives: inflammatory diseases

November, 2018

October, 2018

May, 2018

December, 2017

  • 15 December

    FDA Approves Pfizer’s Ixifi, a Biosimilar to Remicade

    Pfizer Inc. (NYSE:PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved IXIFI™ (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade® (infliximab)* for all eligible indications of the reference product.1 The FDA has approved IXIFI as …

July, 2017

February, 2017

January, 2017

December, 2016

November, 2016

  • 30 November

    Momenta’s Humira Biosimilar Succeeds in Late-Stage Psoriasis Study

    CAMBRIDGE, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that the confirmatory Phase 3 clinical study of M923, a biosimilar HUMIRA® (adalimumab) candidate developed in collaboration with Baxalta, now part of Shire plc, in patients with moderate-to-severe chronic plaque psoriasis, met its primary endpoint. The proportion …